A phase I clinical study tested, in AdCC, the efficacy of brontictuzumab (the molecule is indicated as OMP-52M51), a human-specific monoclonal antibody directed against the Notch1 protein, revealing the effectiveness of this molecule, which is able to repress the proliferation of tumor cells, block the EMT process, often responsible for metastasis, and promote ferroptosis, revealing an enormous therapeutic potential of this antibody [96]. The gene discussed is NOTCH1; the disease is neoplasm.